Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


04.02.2019

1 BMC Cancer
2 Cancer
2 Eur J Dermatol
1 Int J Cancer
1 J Am Acad Dermatol
2 J Invest Dermatol
3 Melanoma Res
2 Oncogene
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. KHAN MA, Akram T, Sharif M, Shahzad A, et al
    An implementation of normal distribution based segmentation and entropy controlled features selection for skin lesion detection and classification.
    BMC Cancer. 2018;18:638.
    PubMed     Text format     Abstract available


    Cancer

  2. GIBNEY GT, Atkins MB
    Choice of first-line therapy in metastatic melanoma.
    Cancer. 2019 Jan 29. doi: 10.1002/cncr.31774.
    PubMed     Text format    

  3. OTT PA, Pavlick AC, Johnson DB, Hart LL, et al
    A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
    Cancer. 2019 Jan 28. doi: 10.1002/cncr.31892.
    PubMed     Text format     Abstract available


    Eur J Dermatol

  4. FRINGS VG, Goebeler M, Kneitz H
    Dermpath & Clinic: In situ melanoma arising within a speckled lentiginous nevus.
    Eur J Dermatol. 2018;28:857-859.
    PubMed     Text format    

  5. GUTZMER R, Harrington KJ, Hoeller C, Lebbe C, et al
    Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
    Eur J Dermatol. 2018;28:736-749.
    PubMed     Text format     Abstract available


    Int J Cancer

  6. FRANKE V, Berger DMS, Klop WMC, van der Hiel B, et al
    High Response Rates for T-VEC in Early Metastatic Melanoma (Stage IIIB/C-IVM1a).
    Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32172.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  7. GASSENMAIER M, Keim U, Leiter U, Eigentler TK, et al
    Age as key factor for pattern, timing and extent of distant metastasis in patients with cutaneous melanoma. A study of the German Central Malignant Melanoma Registry.
    J Am Acad Dermatol. 2019 Jan 28. pii: S0190-9622(19)30151.
    PubMed     Text format     Abstract available


    J Invest Dermatol

  8. INOZUME T, Yaguchi T, Ariyasu R, Togashi Y, et al
    Analysis of the tumor reactivity of tumor-infiltrating lymphocytes in a metastatic melanoma lesion that lost MHC class I expression after anti-PD-1 therapy.
    J Invest Dermatol. 2019 Jan 23. pii: S0022-202X(19)30023.
    PubMed     Text format     Abstract available

  9. NIKBAKHT N, Tiago M, Erkes DA, Chervoneva I, et al
    BET inhibition modifies melanoma infiltrating T cells and enhances response to PD-L1 blockade.
    J Invest Dermatol. 2019 Jan 28. pii: S0022-202X(19)30026.
    PubMed     Text format    


    Melanoma Res

  10. IACONO D, Basile D, Gerratana L, Vitale MG, et al
    Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma.
    Melanoma Res. 2019 Jan 29. doi: 10.1097/CMR.0000000000000584.
    PubMed     Text format     Abstract available

  11. STENEHJEM DD, Au TH, Ngorsuraches S, Ma J, et al
    Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center.
    Melanoma Res. 2019 Jan 25. doi: 10.1097/CMR.0000000000000572.
    PubMed     Text format     Abstract available

  12. MARASIGAN V, Guvenc C, van den Oord JJ, Stas M, et al
    Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcome.
    Melanoma Res. 2019 Jan 23. doi: 10.1097/CMR.0000000000000578.
    PubMed     Text format     Abstract available


    Oncogene

  13. PEROTTI V, Baldassari P, Molla A, Vegetti C, et al
    Correction to: NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
    Oncogene. 2019 Jan 28. pii: 10.1038/s41388-019-0679.
    PubMed     Text format     Abstract available

  14. EL KHARBILI M, Agaesse G, Barbollat-Boutrand L, Pommier RM, et al
    Tspan8-beta-catenin positive feedback loop promotes melanoma invasion.
    Oncogene. 2019 Jan 24. pii: 10.1038/s41388-019-0691.
    PubMed     Text format     Abstract available


    PLoS One

  15. WODLEJ C, Riedl S, Rinner B, Leber R, et al
    Interaction of two antitumor peptides with membrane lipids - Influence of phosphatidylserine and cholesterol on specificity for melanoma cells.
    PLoS One. 2019;14:e0211187.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: